Skip to content
Screener

Viatris VTRS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

McKesson logo
McKessonMCK
$23M+4.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$308K-75.2%
AMP
Amphastar PharmaceuticalsAMPH
$1.98M
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$1K
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$62K-91.4%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$42K-93.9%

Other financials

Income statement

See full
Revenue$3.8B+4.9%
Gross profit$1.5B+9.3%
Operating income$6.3M-97.3%
Net income-$118.8M-2,483%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$890.0M+56.7%
Total debt$13.6B-7.7%
Total equity$14.3B-8.4%
Total assets$35.0B-8.8%

Cash flow

See full
Operating cash flow$381.8M+73.8%
CapEx$52.8M-0.2%
Free cash flow$329.0M+97.2%

Valuation

See full
Market cap$20.55B+84.7%
Enterprise value$33.29B+29.6%
P/S1.4×+0.6×

Profitability

See full
Gross margin34.8%-1.8pp
Operating margin-0.6%
Net margin-2.8%-1.3pp
FCF margin13.3%+0.9pp

Returns & leverage

See full
Return on equity-2.8%-1.3pp
Debt / equity0.0×
Current ratio1.6×+0.2×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The source filing: Viatris’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001792044-26-000041
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Contingent consideration payments(11.4)(13.1)
Payments of financing fees(3.0)(1.0)
Cash dividends paid(279.4)(283.1)
Issuance of common stock1.21.3
Other items, net(24.8)(155.0)
Net cash used in financing activities(1,446.4)(829.4)
Effect on cash of changes in exchange rates(7.5)23.5
Net decrease in cash, cash equivalents and restricted cash(458.0)(168.3)

ITEM 6. [Exhibits](#i61e5533529bd4b8b8b580f5cad6a41ec_190) [74](#i61e5533529bd4b8b8b580f5cad6a41ec_190)

FAQ

What is Viatris's stock issuance proceeds?
Viatris (VTRS) reported stock issuance proceeds of $700K in Q2 2026.
How has Viatris's stock issuance proceeds changed year-over-year?
Viatris's stock issuance proceeds decreased by 0.0% year-over-year, from $700K to $700K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Viatris's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude